Chiasma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 85
- Market Cap
- -
- Website
- https://chiasma.com
Clinical Trials
39
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03252353
- Locations
- 🇺🇸
Keck Medical Center of University of Southern California, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT02685709
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Keck Medical Center of University of Southern California, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Chiasma, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01412424
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇩🇪Campus Charité Mitte, Berlin, Germany
🇩🇪ENDOC Center for Endocrine Tumors, Hamburg, Germany